Filana Therapeutics
FLNA
149 hedge funds and large institutions have $279M invested in Filana Therapeutics in 2022 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 39 increasing their positions, 51 reducing their positions, and 28 closing their positions.
2% less call options, than puts
Call options by funds: $106M | Put options by funds: $109M
1.36% less ownership
Funds ownership: 26.25% → 24.89% (-1.4%)
9% less funds holding
Funds holding: 163 → 149 (-14)
24% less repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 51
28% less capital invested
Capital invested by funds: $390M → $279M (-$111M)
43% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 28
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BNP Paribas Financial Markets
Paris,
France
|
+$5.5M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$2.85M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.84M |
| 4 |
Morgan Stanley
New York
|
+$1.74M |
| 5 |
JG
Jefferies Group
New York
|
+$1.49M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Group One Trading
Chicago,
Illinois
|
-$5.18M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$4.47M |
| 3 |
National Bank of Canada
Montreal,
Quebec, Canada
|
-$2.98M |
| 4 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$2.58M |
| 5 |
Principal Financial Group
Des Moines,
Iowa
|
-$2.3M |
FLNA Hedge Fund Activity: Q2 2022 in Review
149 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Filana Therapeutics (FLNA) for Q2 2022, worth a combined $279M — down 28% from $390M a quarter earlier.
Sellers outnumbered buyers: 28 funds closed out of FLNA and 16 opened new positions — a net loss of 12 holders — while 51 trimmed existing stakes and 39 added.
The largest buyer was BNP Paribas Financial Markets, adding an estimated $5.5M. The largest seller was Group One Trading, cutting an estimated $5.18M.
- 149 institutional investors held Filana Therapeutics (FLNA) as of Q2 2022, down from 163 in Q1 2022.
- Funds reported $279M of Filana Therapeutics stock for Q2 2022, down 28% quarter-over-quarter.
- 16 funds opened new Filana Therapeutics positions in Q2 2022 and 28 closed out, a net change of -12 holders.
- The largest Filana Therapeutics buyer in Q2 2022 was BNP Paribas Financial Markets, an estimated $5.5M added.
- The largest Filana Therapeutics seller in Q2 2022 was Group One Trading, an estimated $5.18M sold.
Based on aggregated 13F filings for Q2 2022.